VEGFB Antikörper

Produktnummer ABIN1589909

Dieser Kaninchen Polyklonal Antikörper erkennt spezifisch VEGFB in WB. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für VEGFB Antikörper (ABIN1589909)

Target: VEGFB (Vascular Endothelial Growth Factor B (VEGFB))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser VEGFB Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Produktdetails anti-VEGFB Antikörper

Verwendungszweck: VEGF-B antibody

Spezifität: Recombinant human VEGF-B167

Aufreinigung: Protein A purified

Immunogen: Recombinant human VEGF-B167

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western Blot: Use 2-5 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS

Handhabung: Centrifuge vial prior to opening.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Haltbarkeit: 24 months

Details zu VEGFB

Target: VEGFB (Vascular Endothelial Growth Factor B (VEGFB))

Hintergrund: Vascular endothelial growth factor B, VEGFB, VRF, VEGFL,Vascular endothelial growth factor B (VEGF-B), also known as vascular endothelial growth factor-related factor (VRF), is a member of the VEGF family of growth factors that share structural and functional similarity. Five mammalian members, including VEGF-A, B, C, D and PlGF, have been identified. VEGF family members are disulfide-linked dimeric proteins that are important regulators of physiological and pathological vasculogenesis, angiogenesis and lymphangiogenesis. VEGF-B is expressed in most tissues, especially in heart, skeletal muscle and pancreas. In many tissues, VEGF-B is coexpressed and can heterodimerize with VEGF. By alternative splicing, two isoforms of mature VEGF-B containing 167 or 186 amino acid (aa) residues exist. The two VEGF-B isoforms have identical amino-terminal cysteine knot VEGF homology domains but the carboxyl end of VEGF-B167 differs from that of VEGF-B186 by the presence of a highly basic cysteine-rich heparin binding domain. Whereas VEGF-B186 is a secreted diffusible protein, VEGF-B167 is sequestered into the cell matrix after secretion. Both VEGF-B isoforms bind VEGF receptor 1 (VEGFR-1), but not VEGFR-2 or VEGFR-3. On endothelial cells, ligation of VEGFR-1 by VEGF-B has been shown to regulate the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1. VEGF-B167 and a proteolytically processed form of VEGF-B186 (VEGF-B127) also bind neuropilin1 (NP1), a type I transmembrane receptor for semaphorins/collapsins, ligands involved in neuron guidance (6). Besides VEGF-B, NP1 has been shown to bind PlGF-2, VEGF165 and VEGFR-1. The many interactions of NP1 with VEGF ligands and receptor suggest that NP1 may function as a regulator of angiogenesis.

Gen-ID: 7423

NCBI Accession: NM_003377, NP_003368

UniProt: P49765

Pathways: RTK Signalweg, Signaling Events mediated by VEGFR1 and VEGFR2, VEGFR1 Specific Signals